RELI
Reliance Global Group, Inc. Common Stock
stock NASDAQ

Wish I hopped on the MRIN train at pre market. Volatile but would’ve made some good gains on that spike to 1.20. I probably should’ve sold my SLrX on the morning spike but I held. We will see what happens. Anyone on RELI got out good as well.

Been watching RELI since the insurtech hype days. This is the first move that feels like they’re playing offense not defense.

Need RELI to go back up so I can dip out

If this Fortman sale and Spetner buy both close, $RELI could look like a much more streamlined and higher-quality business a year from now. Really curious to see how it plays out

Debating MLGO or RELI unsure which dont have much to put in so cant really do both

Saw this update from $RELI yesterday and wanted to share. They announced that they signed a non-binding LOI to sell Fortman Insurance Agency (one of their subsidiaries) for $5 million in cash. What caught my attention is that this price is higher than what they originally paid for it, so it looks like they improved the business after buying it.
Digging in a bit more, looks like since they bought Fortman, they upgraded the systems and brought in a new leadership team. Now the agency is running more efficiently and has more customers. If this sale goes through, $RELI plans to use the cash to help fund the acquisition of another insurance platform called Spetner Associates, which has been growing pretty fast. The company also said that the deal still needs to go through due diligence and final agreements.
Curious if anyone here has been following $RELI or has more info on this potential Spetner deal or what the overall game plan is. Would love to hear more from anyone who’s been tracking this one

RELI

Disclaimer: The generation of this watchlist is automated using a combination of python scripts, trusted financial APIs (i.e. Finnhub, Alphavantage, etc). AI Agents, and LLMs (local purpose built and OpenAI's API). Like any other watchlist, a set of criteria was established and matching tickers were identified. Additional data (news, intraday, etc) was collected for the initial list (usually 50 - 60 tickers) which was then formatted and fed to AI to analyze and identify a top 10. There are mechanisms in place to validate data and ensure accuracy (e.g. pull and compare intraday data from 2 sources) however, errors can occur . This is just a watchlist.. Please do your own DD! This is not financial advice.
**Number of Tickers Analyzed:** 55
**Analysis Approach**
• Gap Analysis: Focused on high absolute post-market gap (%) for intraday momentum.
• Volume Metrics: Required volume ≥150% of 10-day average for liquidity.
• Technical Range: Noted proximity to 52-week highs/lows for pivot plays.
• News Sentiment: Weighted recent strong positive/negative stories as catalysts.
• Earnings Catalyst: None in next 14 days.
• Insider Activity: Gave extra weight to positive insider buys (GALT).
• Price Action Consistency: Confirmed with gap + sustained volume spikes.
**Bullet-Point Explanation for Each Stock**
**1. VERV (Score 9.8)**
• Acquisition by Eli Lilly announced; shares soared \~75% intraday (Bullish, 0.483)
• Volume 2,509% of avg and trading above 52-week high — strong breakout
**2. GALT (9.3)**
• Insiders bought \~$699K in past 21 days, reinforcing near-term upside
• Volume 756% of avg, minor gap, trading near mid-range; insider catalyst
**3. PCSA (9.0)**
• Shares up \~150% on gastroparesis drug licensing to Intact (Bullish, 0.455)
• Volume 10,519% of avg and positive gap — high volatility play
**4. CERO (8.8)**
• FDA granted Orphan Drug Designation for lead candidate; bullish sentiment
• Volume 66,513% of avg; large post-market drop (–15.8%) offers intraday reversal
**5. ACXP (8.5)**
• Phase 2b trial results published in *The Lancet Microbe* — shares +135%
• Volume 886% of avg, post-market gap –12.9% for potential bounce
**6. XAIR (8.3)**
• Q4 earnings due June 17 — analyst attention; volume 1,510% of avg
• Post-market gap –18% suggests volatility for scalping
**7. RELI (8.2)**
• Volume 1,623% of avg and +41% gap; proximity to 52-week low may trigger mean-reversion
• Neutral news but extreme volume and gap
**8. SDST (8.0)**
• Volume 4,597% of avg with +13.7% gap; strong liquidity
• No news but large gap & volume
**9. SLRX (7.8)**
• Conditional Nasdaq extension; shares +50%
• Volume 4,522% of avg, moderate post-market dip for intraday setups
**10. RBNE (7.5)**
• Volume 313% of avg and +12% gap; some bullish sentiment on market strength
• Trading midway to 52-week high — momentum candidate
**Catalyst Highlights**
• **VERV**: Definitive acquisition agreement with Eli Lilly
• **GALT**: Significant insider buying within last 7 days
• **PCSA**: Major licensing deal driving 150% move
• **XAIR**: Upcoming earnings release
• **CERO / ACXP**: FDA/trial news with strong sentiment
**Additional Observations**
• Micro-caps (CERO, XAIR, SDST) offer highest volatility but higher risk
• Insiders in GALT provide a strong directional clue
• Look for intraday reversals on large negative gaps and breakouts on large positive gaps
• Monitor continuous volume prints and Level 2 for order flow on these names

Wish I hopped on the MRIN train at pre market. Volatile but would’ve made some good gains on that spike to 1.20. I probably should’ve sold my SLrX on the morning spike but I held. We will see what happens. Anyone on RELI got out good as well.

Been watching RELI since the insurtech hype days. This is the first move that feels like they’re playing offense not defense.

Need RELI to go back up so I can dip out

If this Fortman sale and Spetner buy both close, $RELI could look like a much more streamlined and higher-quality business a year from now. Really curious to see how it plays out

Debating MLGO or RELI unsure which dont have much to put in so cant really do both

Saw this update from $RELI yesterday and wanted to share. They announced that they signed a non-binding LOI to sell Fortman Insurance Agency (one of their subsidiaries) for $5 million in cash. What caught my attention is that this price is higher than what they originally paid for it, so it looks like they improved the business after buying it.
Digging in a bit more, looks like since they bought Fortman, they upgraded the systems and brought in a new leadership team. Now the agency is running more efficiently and has more customers. If this sale goes through, $RELI plans to use the cash to help fund the acquisition of another insurance platform called Spetner Associates, which has been growing pretty fast. The company also said that the deal still needs to go through due diligence and final agreements.
Curious if anyone here has been following $RELI or has more info on this potential Spetner deal or what the overall game plan is. Would love to hear more from anyone who’s been tracking this one

RELI

Disclaimer: The generation of this watchlist is automated using a combination of python scripts, trusted financial APIs (i.e. Finnhub, Alphavantage, etc). AI Agents, and LLMs (local purpose built and OpenAI's API). Like any other watchlist, a set of criteria was established and matching tickers were identified. Additional data (news, intraday, etc) was collected for the initial list (usually 50 - 60 tickers) which was then formatted and fed to AI to analyze and identify a top 10. There are mechanisms in place to validate data and ensure accuracy (e.g. pull and compare intraday data from 2 sources) however, errors can occur . This is just a watchlist.. Please do your own DD! This is not financial advice.
**Number of Tickers Analyzed:** 55
**Analysis Approach**
• Gap Analysis: Focused on high absolute post-market gap (%) for intraday momentum.
• Volume Metrics: Required volume ≥150% of 10-day average for liquidity.
• Technical Range: Noted proximity to 52-week highs/lows for pivot plays.
• News Sentiment: Weighted recent strong positive/negative stories as catalysts.
• Earnings Catalyst: None in next 14 days.
• Insider Activity: Gave extra weight to positive insider buys (GALT).
• Price Action Consistency: Confirmed with gap + sustained volume spikes.
**Bullet-Point Explanation for Each Stock**
**1. VERV (Score 9.8)**
• Acquisition by Eli Lilly announced; shares soared \~75% intraday (Bullish, 0.483)
• Volume 2,509% of avg and trading above 52-week high — strong breakout
**2. GALT (9.3)**
• Insiders bought \~$699K in past 21 days, reinforcing near-term upside
• Volume 756% of avg, minor gap, trading near mid-range; insider catalyst
**3. PCSA (9.0)**
• Shares up \~150% on gastroparesis drug licensing to Intact (Bullish, 0.455)
• Volume 10,519% of avg and positive gap — high volatility play
**4. CERO (8.8)**
• FDA granted Orphan Drug Designation for lead candidate; bullish sentiment
• Volume 66,513% of avg; large post-market drop (–15.8%) offers intraday reversal
**5. ACXP (8.5)**
• Phase 2b trial results published in *The Lancet Microbe* — shares +135%
• Volume 886% of avg, post-market gap –12.9% for potential bounce
**6. XAIR (8.3)**
• Q4 earnings due June 17 — analyst attention; volume 1,510% of avg
• Post-market gap –18% suggests volatility for scalping
**7. RELI (8.2)**
• Volume 1,623% of avg and +41% gap; proximity to 52-week low may trigger mean-reversion
• Neutral news but extreme volume and gap
**8. SDST (8.0)**
• Volume 4,597% of avg with +13.7% gap; strong liquidity
• No news but large gap & volume
**9. SLRX (7.8)**
• Conditional Nasdaq extension; shares +50%
• Volume 4,522% of avg, moderate post-market dip for intraday setups
**10. RBNE (7.5)**
• Volume 313% of avg and +12% gap; some bullish sentiment on market strength
• Trading midway to 52-week high — momentum candidate
**Catalyst Highlights**
• **VERV**: Definitive acquisition agreement with Eli Lilly
• **GALT**: Significant insider buying within last 7 days
• **PCSA**: Major licensing deal driving 150% move
• **XAIR**: Upcoming earnings release
• **CERO / ACXP**: FDA/trial news with strong sentiment
**Additional Observations**
• Micro-caps (CERO, XAIR, SDST) offer highest volatility but higher risk
• Insiders in GALT provide a strong directional clue
• Look for intraday reversals on large negative gaps and breakouts on large positive gaps
• Monitor continuous volume prints and Level 2 for order flow on these names